Skip to main content

Table 2 Propensity-score matching of statin-treated with non statin-treated patients

From: Hepatic transcriptomic signatures of statin treatment are associated with impaired glucose homeostasis in severely obese patients

  Statin group (n = 157) Non-statin group (n = 157) Effect size Values (95% CI) P value
Diabetes 117 (75.1) 83 (53.0) Odds ratio 2.67 (1.60 to 4.45) 0.0002
Patients on antidiabetic drugs 110 (70.5) 67 (42.9) Odds ratio 3.18 (1.96 to 5.15) < 0.0001
Patients with number of antidiabetic drugs
 0 46 (29.5) 89 (57.1) Common odds ratio 2.88 (1.83 to 4.53) < 0.0001
 1 39 (24.7) 27 (17.0)    
 2 26 (17.0) 18 (11.6)    
 > 2 45 (28.8) 22 (14.3)    
Patients on insulin treatment 42 (26.8) 23 (14.4) Odds ratio 2.17 (1.25 to 3.74) 0.006
Fasting blood glucose [mmol/L] 7.1 (5.9 to 10.1) 6.0 (5.4 to 8.0) Mean differencea 0.14 (0.06 to 0.22) 0.0002
2 h blood glucose [mmol/L] 11.6 (7.4 to 17.0) 9.0 (6.6 to 13.8) Mean differencea 0.18 (0.06 to 0.29) 0.002
HbA1c [%] 6.8 (6.0 to 8.2) 6.2 (5.7 to 7.1) Mean differencea 0.09 (0.04 to 0.14) 0.0001
  1. The comparison of the main patient characteristics between statin and non-statin treatment groups after propensity score-matching and multiple imputation is shown. Values are presented as n (%) or median (IQR) unless otherwise indicated. acalculated on log-transformed data. Abbreviations: HbA1c hemoglobin A1c